Search

everythinglearnresearchcommunity

for

Search:↓

Treatment for benign prostatic hyperplasia involves drugs that either quickly relieve symptoms or reduce prostate size, with a combination offering more benefits but more side effects.

Medical treatments for benign prostatic hyperplasia mainly relieve symptoms, while surgery is more effective but not always suitable for elderly patients.

5α-reductase inhibitors help manage symptoms of benign prostatic hyperplasia and may also prevent prostate cancer and treat hair loss.

5-alpha reductase inhibitors help with benign prostatic hyperplasia but don't cure it, and more research is needed.

5-alpha reductase inhibitors may have additional effects on cancer, mental health, heart health, and hormone levels beyond treating prostate enlargement.

Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.

Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.

Accurate protein modeling can help develop new treatments for prostate cancer and other diseases.

Certain Egyptian Sabal fruit extracts may help treat anti-androgenic diseases like benign prostatic hyperplasia.

The conclusion is that using drugs to block the TOR pathway might slow aging and prevent age-related diseases.

New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.

Normal levels of DHT can reduce belly fat and increase muscle, but too much can lead to hair loss, prostate issues, and possibly heart disease.

The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.

CEC levels may be a useful marker for predicting prostate cancer progression.

Larger prostate size in older men may be linked to poorer semen quality and fertility issues.

Eosinophilic cystitis is often misdiagnosed, but accurate diagnosis and treatment improve outcomes.

Dutasteride effectively treats benign prostatic hyperplasia and may reduce prostate cancer risk.

5αR inhibitors help slow early prostate cancer cell growth, suggesting combined treatments are needed.

Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.

Finasteride effectively reduces prostate size and symptoms in most BPH patients.

Finasteride overdose can cause acute pancreatitis.

Evidence-based urology improved treatment and quality of life for conditions like BPH by shifting from surgery to effective medications like finasteride and dutasteride.

Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.

Higher doses of 5α-reductase inhibitors may lower mortality risk, but low doses increase it.

The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.

Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.

5alpha-reductase inhibitors help treat hair loss and prostate issues but may cause sexual side effects.

Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.

A new compound that could treat various androgen-related conditions was created and analyzed.

5ARIs effectively treat and manage BPH by reducing prostate size and symptoms.